Drug Utilisation Sub-Committee Outcome Statement 6-7 June 2013

First Page		Document Content
Date: 2015-03-13 00:20:02 Healthcare in Australia Pharmaceuticals policy Pharmaceutical Benefits Scheme Quality use of medicines Drug safety Fingolimod Cetuximab Pharmacovigilance Antipsychotic Medicine Pharmacology Health		Drug Utilisation Sub-Committee Outcome Statement 6-7 June 2013 Add to Reading List Source URL: www.pbs.gov.au Download Document from Source Website File Size: 117,00 KB Share Document on Facebook

	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1qn6Z - View Document
	Stellungnahme der AkdÄ zur Nutzenbewertung von Fingolimod (neues Anwendungsgebiet) DocID: 1n48S - View Document
	Rote-Hand-Brief zu Gilenya® (Fingolimod) DocID: 1h06f - View Document
	Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators DocID: 1fWCE - View Document
	Bijlage bij email betreffende vergoeding fingolimod juliArtikel uit MenSen nr. 4 Samenvatting aanvullende voorwaarden zoals is overeengekomen op 4 juni 2013 met CVZ, VWS, zorgverzekeraars, MS Vereniging Nederland, DocID: 1ea9n - View Document